华东医药:2024年年度报告(英文版)

Huadong Medicine Co., Ltd.
2024Annual Report
April 2025

ALetter to the Shareholders
Distinguished shareholders,
Time tempers our original aspiration, and transformation propels us forward. As
the tides of era surge, we persevere like determined climbers, moving with deliberate
persistenceandrisingwithsteadfaststrides.Theyear2024markedayearofformidable
challenges and steady yet significant progress for Huadong Medicine Co., Ltd.
(“Huadong Medicine”, “we” or “the Company”). We successfully completed our 7th
three-year plan, marked significant strides in innovation and transformation, and
advanced our R&D pipelines to the acceptance phase. Moreover, all four of our core
business segments achieved accelerated growth, a direct testament to the dedication
and perseverance behind these results. The Company is now operating on a high-
quality development trajectory, with revenue and net profit attributable to shareholders
having grown by 21.24% and 52.59% respectively since 2021, continually setting new
historical records. Our teammaintainsstrategic focus whilestrengthening foundational
capabilities, renewing the Company’s vibrant image and driving continuous
transformation.
As we look back on our journey, each step has been illuminated by innovation,
leading to a thriving
……